FDA Accepts New Application for ZORYVE® Cream in Children
In an exciting development for pediatric dermatology, the FDA has accepted a supplemental New Drug Application (sNDA) submitted by Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) for ZORYVE® (roflumilast) cream 0.3%. This once-daily topical treatment aims to expand its indication for the treatment of plaque psoriasis to include children aged 2 to 5 years. The Prescription Drug User Fee Act (PDUFA) has set a target action date, allowing families and healthcare providers to anticipate potential availability by mid-2026.
Significance of ZORYVE for Pediatric Patients
Providing effective treatments for plaque psoriasis in young children can be challenging, especially since the disease can affect sensitive skin areas, including the face and skin folds. Dr. Amy Paller, a respected expert in dermatology, emphasizes the necessity for well-tolerated therapies that can safely address the unique needs of this vulnerable population. With the acceptance of this application, ZORYVE cream could become the first and only topical phosphodiesterase-4 (PDE4) inhibitor indicated for such young patients, presenting a non-steroidal option that balances tolerability with efficacy.
Clinical Data Supporting the Application
Currently, ZORYVE cream is approved for treating plaque psoriasis in patients six years and older. The sNDA is underpinned by crucial data collected from both a 4-week Maximal Usage Systemic Exposure (MUSE) study specifically involving children aged 2 to 5, as well as from a long-term open-label study. These studies collectively demonstrate ZORYVE’s long-term safety, tolerability, and sustained efficacy, reflecting its suitability for pediatric use.
Understanding Plaque Psoriasis
Plaque psoriasis is a chronic inflammatory skin condition affecting millions across the United States, with symptoms including itchiness, scaling, and discomfort. It poses unique treatment challenges, especially in children, as the disease often manifests in sensitive areas. Addressing these needs requires a nuanced approach, ensuring that treatments are gentle yet effective enough to manage symptoms and enhance the quality of life of young patients and their families.
ZORYVE: A Breakthrough in Topical Treatments
ZORYVE is an advanced topical formulation that inhibits the PDE4 enzyme, a key target in dermatological treatments. By reducing the production of pro-inflammatory mediators, ZORYVE plays a vital role in lowering skin inflammation and normalizing the immune response in affected individuals. This promise of efficacy has positioned ZORYVE as a leading option in the treatment of various inflammatory skin conditions.
Acknowledgments and Recognition
The impact of ZORYVE has been recognized widely within the dermatological community. It recently received accolades, including the prestigious 2025 Best of Beauty Breakthrough Award from Allure, marking it as the first FDA-approved medication for multiple inflammatory dermatoses to earn such a title. Its efficacy and safety have also earned it the National Psoriasis Foundation’s Seal of Recognition, highlighting its position as a trusted prescription therapy.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is dedicated to innovation in medical dermatology. The company is committed to addressing the immediate requirements of individuals dealing with immune-mediated skin diseases. With an impressive pipeline of advanced targeted topicals, Arcutis aims to elevate treatment standards across a variety of inflammatory skin conditions, ensuring that dermatological advancements benefit patients of all ages.
Frequently Asked Questions
What is ZORYVE cream used for?
ZORYVE cream is indicated for topical treatment of plaque psoriasis in patients aged 2 years and older, providing a non-steroidal option for managing this condition.
What does the FDA acceptance mean for ZORYVE?
The FDA's acceptance of the sNDA signifies the potential for ZORYVE to be available for younger pediatric patients suffering from plaque psoriasis.
How does ZORYVE work?
ZORYVE inhibits the phosphodiesterase-4 enzyme, which helps to reduce inflammation and normalize the immune response in the skin.
Who can use ZORYVE cream?
ZORYVE is suitable for patients aged 2 years and older, including children, positioned as a gentle and effective treatment option for plaque psoriasis.
What are the potential side effects of ZORYVE?
Some common side effects may include diarrhea, headache, and application site pain, but it is generally well tolerated among users.
